Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

LIPIDEMIA Initiation Mechanisms of Lipid-driven Diseases

Coordinator
Karolinska Institutet, Sweden
Runs
1 November 2023 to 31 October 2025
Status
Running
EU funding
€207k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101105531

What the project is doing

In the project's own words, from its summary on CORDIS.

The metabolic syndrome and its several manifestations have currently taken a tremendous toll on many aspects of society. Nonalcoholic fatty liver disease (NAFLD) is considered the liver component of the metabolic syndrome while atherogenic dyslipidaemia, and especially apolipoprotein B (ApoB)-containing lipoproteins, is considered the major causal mechanism in atherosclerosis initiation and progression. By employing novel humanized mouse models that can be rendered acutely dyslipidemic, we have already demonstrated that, at the very onset of dyslipidemia, ApoB-containing lipoproteins interact with immune cells in the liver causing immune and metabolic changes, including ectopic lipid deposition.

This opened to the idea that the inflammatory response evoked by acute dyslipidemia plays a pivotal role in the initiation of other important lipid-driven diseases such as NAFLD. Hereafter, we present experiments to elucidate novel mechanisms central to the pathogenesis of NAFLD. We will better define the nature of the innate immune cells that firstly react to a dyslipidemic insult. This will be accomplished by imaging the different hepatic macrophage subsets after transition to dyslipidemia and by examining the physiological changes caused by liver Kupffer cells depletion.

Secondly, we will investigate how this initial hepatic response will in turn affect atherosclerosis initiation and progression. We will target atherogenic factors secreted by liver immune cells upon ApoB uptake and inhibit several of them in vivo using neutralizing antibodies. Finally, by employing 2H2O to trace lipids' synthetic rates, we will clarify whether the hepatic lipid accumulation observed in our mice is of endogenous or exogenous sources.

This project will yield powerful insights on targetable mechanisms concerning the initiation rather than the end-state of metabolic diseases that are currently endemic to the global population, opening to earlier detection and intervention.

Topics

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI